The infusion center business makes up approximately half of the typical health system’s drug spend. While reimbursement for outpatient cancer drugs are generally favorable, most hospital outpatient infusion centers struggle financially. Their financial sustainability is under increased threat due to recent changes to the 340B drug pricing problem, emerging site-of-care policies from private payers, and rising drug prices.
Use this cheat sheet to quickly get up to speed on the infusion center business, why it increasingly demands attention from health system executives, and how program leaders need to respond.
Next, check out
2017 survey results: The top cancer program threats and opportunities